• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Non-canonical Notch Signaling Regulates Actin Remodeling in Cell Migration by Activating PI3K/AKT/Cdc42 Pathway
In conclusion, our research results indicate that DAPT activates PI3K/AKT/Cdc42 signaling by non-canonical Notch pathway, and the activated Cdc42 promotes the filopodia formation and inhibits lamellipodia assembly, resulting in reduced migration of breast cancer cells. The results imply that non-canonical Notch signaling may play a very important role in the rapid response of cells to the extracellular signals. Author Contributions LG, JD, and LL designed the study and wrote and revised the manuscript. LL and LZ performed most of the experiments and data analysis. SZ, X-YZ, P-XM, Y-DM, Y-YW, YC, S-JT, and Y-JZ assisted i...
Source: Frontiers in Pharmacology - April 15, 2019 Category: Drugs & Pharmacology Source Type: research

Connecting Metainflammation and Neuroinflammation Through the PTN-MK-RPTP β/ζ Axis: Relevance in Therapeutic Development
Conclusion The expression of the components of the PTN-MK-RPTPβ/ζ axis in immune cells and in inflammatory diseases suggests important roles for this axis in inflammation. Pleiotrophin has been recently identified as a limiting factor of metainflammation, a chronic pathological state that contributes to neuroinflammation and neurodegeneration. Pleiotrophin also seems to potentiate acute neuroinflammation independently of the inflammatory stimulus while MK seems to play different -even opposite- roles in acute neuroinflammation depending on the stimulus. Which are the functions of MK and PTN in chronic neuroi...
Source: Frontiers in Pharmacology - April 11, 2019 Category: Drugs & Pharmacology Source Type: research

Prenylated Xanthones from Metaxya rostrata suppress FoxM1 and induce active cell death by distinct mechanisms
ConclusionIn summary, our data clearly showed that XB and OH-XB are promising new lead compounds for cancer therapy with distinct cellular mechanisms. Both compounds are candidates for further pre-clinical and clinical investigations.Graphical abstract
Source: Phytomedicine - April 3, 2019 Category: Drugs & Pharmacology Source Type: research

Apoptosis of A549 cells by small interfering RNA targeting survivin delivery using poly-β-amino ester/guanidinylated O-carboxymethyl chitosan nanoparticles
This study focuses on guanidinylated O-carboxymethyl chitosan (GOCMCS) along with poly-β-amino ester(PBAE) for siRNA delivery. Binding efficiency of PBAE/siRNA/GOCMCS nanoparticles were characterized by gel electrophoresis. The siRNA-loaded nanoparticles were found to be stable in the presence of RNase A, serum and BALF respectively. Fine particle fraction (FPF) which was determined by a two-stage impinger (TSI) was 57.8% ± 2.6%. The particle size and zeta potential of the nanoparticles were 153.8 ± 12.54 nm and +12.2 ± 4.94 mV. In vitro cell transfection studies were carried out with A549 cells. The cellular uptake wa...
Source: Asian Journal of Pharmaceutical Sciences - November 28, 2018 Category: Drugs & Pharmacology Source Type: research

TARGETED LIPOSOMES FOR siRNA DELIVERY TO CANCER.
CONCLUSION: siRNA delivery mediated by functionalized liposomes is promising, but clinical trials need to be conducted. PMID: 30084323 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - August 7, 2018 Category: Drugs & Pharmacology Authors: Eloy JO, Petrilli R, Raspantini GL, Lee RJ Tags: Curr Pharm Des Source Type: research

Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
This study aimed to improve targeted delivery and enhance therapeutic efficacy for tumor anti-angiogenesis. The HA-CH-NP/siRNA was 200 ± 10 nm in size with a zeta potential of 26.4 mV. The loading efficiency of siRNA to the HA-CH-NP/siRNA was up to 60%. The selective binding of HA-CH-NP/siRNA to CD44-positive tumor endothelial cells increased by 2.1-fold compared with that of the CD44 nontargeted CH-NP/siRNA. PLXDC1 silencing by the HA-CH-NP/siRNA significantly inhibited tumor growth in A2780 tumor-bearing mice compared with that in the control group (p < .01), and mRNA expression of PLXDC1 was significantl...
Source: Drug Delivery - June 14, 2018 Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research

Poly (amidoamine) (PAMAM) dendrimer mediated delivery of drug and pDNA/siRNA for cancer therapy
Publication date: 30 July 2018 Source:International Journal of Pharmaceutics, Volume 546, Issues 1–2 Author(s): Jun Li, Huamin Liang, Jing Liu, Ziyuan Wang Poly (amidoamine) (PAMAM) dendrimers are well-defined, highly branched macromolecules with numerous active amine groups on the surface. Because of their unique properties, PAMAM dendrimers have steadily grown in popularity in drug delivery, gene therapy, medical imaging and diagnostic application. This review focuses on the recent developments on the application in PAMAM dendrimers as effective carriers for drug and gene (pDNA, siRNA) delivery in cancer therapy, incl...
Source: International Journal of Pharmaceutics - May 26, 2018 Category: Drugs & Pharmacology Source Type: research

Complexation of Chol-DsiRNA in place of Chol-siRNA greatly increases the duration of mRNA suppression by polyplexes of PLL(30)-PEG(5K) in primary murine syngeneic breast tumors after i.v. administration
Publication date: 30 May 2018 Source:International Journal of Pharmaceutics, Volume 543, Issues 1–2 Author(s): Vishakha V. Ambardekar, Rajesh R. Wakaskar, Zhen Ye, Stephen M. Curran, Timothy R. McGuire, Don W. Coulter, Rakesh K. Singh, Joseph A. Vetro RNA interference has tremendous potential for cancer therapy but is limited by the insufficient potency of RNAi molecules after i.v. administration. We previously found that complexation with PLL(30)-PEG(5K) greatly increases the potency of 3′-cholesterol-modified siRNA [Chol-siRNA] in primary murine syngeneic 4T1 breast tumors after i.v. administration but mRNA suppress...
Source: International Journal of Pharmaceutics - March 30, 2018 Category: Drugs & Pharmacology Source Type: research

Cationic Polymeric Nanoparticle Delivering CCR2 siRNA to Inflammatory Monocytes for Tumor Microenvironment Modification and Cancer Therapy
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.7b00997
Source: Molecular Pharmaceutics - January 26, 2018 Category: Drugs & Pharmacology Authors: Song Shen, Yue Zhang, Kai-Ge Chen, Ying-Li Luo and Jun Wang Source Type: research

ASAP Cationic Polymeric Nanoparticle Delivering CCR2 siRNA to Inflammatory Monocytes for Tumor Microenvironment Modification and Cancer Therapy
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.7b00997
Source: Molecular Pharmaceutics - January 26, 2018 Category: Drugs & Pharmacology Authors: Song Shen, Yue Zhang, Kai-Ge Chen, Ying-Li Luo, Jun Wang Source Type: research

Recent advances in siRNA delivery for cancer therapy using smart nanocarriers.
Abstract Small interfering RNAs (siRNAs) can selectively target and downregulate disease-causing genes, holding great promise in treating human diseases, especially malignant cancers. However, how to efficiently deliver siRNAs into target cell cytosol is a problem that has hindered their clinical application. Here, we review the recent strategies for siRNA delivery on the basis of smart nanocarriers by using stimuli-responsive materials. We highlight the rationales of how to design smart nanocarriers responsive to physiological and external stimuli to improve the delivery efficiency, targeting precision and gene s...
Source: Drug Discovery Today - January 23, 2018 Category: Drugs & Pharmacology Authors: Zhang P, An K, Duan X, Xu H, Li F, Xu F Tags: Drug Discov Today Source Type: research

Therapeutic effects of bach1 siRNA on human breast adenocarcinoma cell line
Conclusion Our results suggest that the bach1 can be considered as a potent adjuvant in breast cancer therapy.
Source: Biomedicine and Pharmacotherapy - January 13, 2017 Category: Drugs & Pharmacology Source Type: research

Therapeutic effects of bach1 siRNA on human breast adenocarcinoma cell line.
CONCLUSION: Our results suggest that the bach1 can be considered as a potent adjuvant in breast cancer therapy. PMID: 28092843 [PubMed - as supplied by publisher]
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - January 12, 2017 Category: Drugs & Pharmacology Authors: Aletaha M, Mansoori B, Mohammadi A, Fazeli M, Baradaran B Tags: Biomed Pharmacother Source Type: research

Doxorubicin and siRNA Codelivery via Chitosan-Coated pH-Responsive Mixed Micellar Polyplexes for Enhanced Cancer Therapy in Multidrug-Resistant Tumors
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.6b00776
Source: Molecular Pharmaceutics - November 8, 2016 Category: Drugs & Pharmacology Authors: Adeel Masood Butt, Mohd Cairul Iqbal Mohd Amin, Haliza Katas, Nor Azian Abdul Murad, Rahman Jamal and Prashant Kesharwani Source Type: research

Curcumin induces G0/G1 arrest and apoptosis in hormone independent prostate cancer DU-145 cells by down regulating Notch signaling
Conclusion Curcumin induced apoptosis and G0/G1 arrest in DU-145 cells by down regulating Notch signaling.
Source: Biomedicine and Pharmacotherapy - September 19, 2016 Category: Drugs & Pharmacology Source Type: research

Pages: 1  2  3  4  5  6  7